thought call
merck result guid gener line share stronger
base view differenti growth profil versu pharma peer inde
merck guidanc revenu adjust ep look cleaner still
beatabl compar pharma peer guid growth revenu
ep earn season view merck stori remain larg
keytruda franchis continu show domin across i/o
greater ou sale contribut ou top consist market share
gain us could drive bigger upsid recogn linger question
potenti competit data next month notabl merck set high
bar like unmatch lung potenti across import
indic like rcc data later month term manag outlook
larg unchang think current environ could conduc
increas deal pace expect potenti deal smaller scale continu
like merck posit rel peer pipelin perspect
look year impress growth forecast top line
ep growth meaning room upsid near term rais
price target vs prior reflect continu confid merck
commerci posit beyond maintain overweight rate
near-term catalyst merck sever higher impact readouts/regulatori event
expect cours year includ rcc feb
pdufa adj melanoma feb pdufa april neoadj /adj
tnbc addit phase dataset expect includ lynparza polo
keytruda readout across multipl indic tnbc sclc
gastric bladder msi-h chl esophag
model chang made model adjust reflect perform
guidanc manag commentari chang ep estim move
revenu remain
quarterli annual ep usd
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
rais usd
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight believ merck like
continu take share lung back
posit data addit kn-
view perhap first-
line lung market share grab us
support ow rate
faster uptak keytruda nsclc i/o
combin data acceler develop
preserv market share de-risk pipelin
posit pipelin data could put upward bia
consensu estim re-rat stock
continu weak core brand like remicad
januvia coupl faster share declin
keytruda pipelin setback could depress
revenu estim forward multipl
million except per share itemspriorcurrentchg chg incom net item net ep ep ep ep outstand outstand analysispriorcurrentchg chg bp gross tax growthpriorcurrentchg chg million except per share itemspriorcurrentchg chg incom net item net ep ep ep ep outstand outstand analysiscurrentcurrentchg chg bp gross tax growthcurrentcurrentchg chg barclay merck co
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
price sourc refinitiv last avail close price relev trade market unless anoth time sourc indic
